Effectiveness and safety of paclitaxel liposome in combination with cisplatin as first-line chemotherapy for advanced squamous lung cancer

杨静翔; 罗虎; 周向东

您当前的位置：

首页 >

文章列表页 >

Effectiveness and safety of paclitaxel liposome in combination with cisplatin as first-line chemotherapy for advanced squamous lung cancer

更新时间：2026-01-09

- Effectiveness and safety of paclitaxel liposome in combination with cisplatin as first-line chemotherapy for advanced squamous lung cancer
- Journal of Army Medical University Vol. 36, Issue 2, Pages: 140-143(2014)
- 作者机构：
- 作者简介：
- 基金信息：
- DOI：
  CLC： R734.2;R969.4;R979.1
- Published：2014
- 稿件说明：
移动端阅览
杨静翔,罗虎,周向东.紫杉醇脂质体对比吉西他滨联合顺铂一线治疗中晚期肺鳞癌的疗效评价[J].陆军军医大学学报(原第三军医大学学报),2014,36(02):140-143.

　Yang Jingxiang,Luo Hu,Zhou Xiangdong.Effectiveness and safety of paclitaxel liposome in combination with cisplatin as first-line chemotherapy for advanced squamous lung cancer[J].J Amry Med Univ (J Third Mil Med Univ),2014,36(02):140-143.
杨静翔,罗虎,周向东.紫杉醇脂质体对比吉西他滨联合顺铂一线治疗中晚期肺鳞癌的疗效评价[J].陆军军医大学学报(原第三军医大学学报),2014,36(02):140-143. DOI：

　Yang Jingxiang,Luo Hu,Zhou Xiangdong.Effectiveness and safety of paclitaxel liposome in combination with cisplatin as first-line chemotherapy for advanced squamous lung cancer[J].J Amry Med Univ (J Third Mil Med Univ),2014,36(02):140-143. DOI：

摘要

目的对比紫杉醇脂质体联合顺铂方案（LP）与吉西他滨联合顺铂方案（GP）一线治疗Ⅲ/Ⅳ期肺鳞癌的临床疗效、毒副作用及远期预后。方法共纳入71例Ⅲ/Ⅳ期鳞癌患者，LP组37例，GP组34例，分别给予注射用紫杉醇脂质体（175 mg/m

）+顺铂（75 mg/m

）和注射用吉西他滨(1 000 mg/m

)+顺铂（75 mg/m

）治疗，21 d为1个周期；2个周期化疗结束后系统评价其疗效。结果对于肺原发灶2组客观缓解率(37.8% vs 32.4%

=0.629)和疾病控制率(83.8% vs 76.5%

P=0.439)差异无统计学意义；对于区域转移的淋巴结2组客观缓解率（45.9% vs 20.6%

=0.024)和疾病控制率(86.5% vs 64.7%

=0.032)均为LP组显著增高。LP组无进展生存期高于GP组（7.0个月vs 5.0个月

=0.014）。LP化疗组血小板减少、恶心及呕吐发生率低于GP化疗组（

0.05）。结论对于伴有区域淋巴结转移的鳞癌患者，LP方案毒副作用更少，可获得更高的无疾病进展生存期，可能更能使患者获益。

Abstract

Objective To compare the effectiveness and safety of paclitaxel liposome plus cisplatin (LP) with gemcitabine plus cisplatin (GP) in advanced lung squamous cell carcinoma (SCC) with regional lymph node metastasis. Methods Seventy-one advanced lung SCC patients were assigned to receive either paclitaxel liposome (175 mg/m

) plus cisplatin (75 mg/m

) (LP group

n=37) or gemcitabine (1 000 mg/m

) pl

us cisplatin (75 mg/m

) (GP group

n=34) every 3 weeks. All patients were treated with at least two 21-day courses

and evaluated by chest CT every two courses. Results No statistical difference was observed between the LP and GP groups in terms of objective response rate (ORR) of lung primary foci (37.8% vs 32.4%

=0.629) and the disease control rate (DCR) of lung primary foci (83.8% vs 76.5%

=0.439). LP group had higher ORR of regional metastasis lymph node (45.9% vs 20.6%

=0.024) and DCR of regional metastasis lymph node (86.5% vs 64.7%

=0.032). Longer progression free survival (PFS) was observed in LP group (7.0 vs 5.0 months

=0.014). LP group was associated with significantly less thrombocytopenia

nausea and emesis(

0.05). Conclusion Paclitaxel liposome plus cisplatin seems to be superior to gemcitabine plus cisplatin for lung SCC treatment with less toxicity

better tolerance and longer PFS.

关键词

Keywords

references

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Efficacy and safety of immunotherapy combined with targeted therapy and chemotherapy in third-line treatment of microsatellite stable metastatic colorectal cancer

Oncolytic influenza virus enhances killing effect of gemcitabine against pancreatic cancer cells—MENG Zihe^1,2, XU Yongru², DENG Zhaoda², ZHANG Yuxin^1,2, YANG Penghui^1,2, HU Ruiping¹ ¹College of Basic Medical Sciences, Inner Mongolia Medical University, Hohhot, Inner Mongolia;²Institute of Hepato-Pancreato-Biliary Surgery, First Medical Center, Chinese PLA General Hospital, Beijing, China

TNIK regulates actin cytoskeleton morphology via Rho/ROCK/LIMK1 pathway in lung adenocarcinoma A549 cells

Preparation of drug-loaded iridium oxidenanocomposites and its application in synergetic sonodynamic/chemotherapeutic therapy against cancer

Clinical treatment for retinoblastoma: report of 118 cases

Related Author

ZHAO Wensi

SONG Jian

孟子鹤

徐永茹

邓肇达

张雨欣

杨鹏辉

扈瑞平

Related Institution

Department of Oncology, Renmin Hospital of Wuhan University

Department of Pharmacy, Renmin Hospital of Wuhan University

内蒙古医科大学基础医学院

中国人民解放军总医院第一医学中心肝胆胰外科医学部研究所

⁰